{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:20:15Z","timestamp":1772083215076,"version":"3.50.1"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,4,5]]},"DOI":"10.18632\/oncotarget.7888","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T13:31:30Z","timestamp":1457011890000},"page":"18638-18650","source":"Crossref","is-referenced-by-count":23,"title":["Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3"],"prefix":"10.18632","volume":"7","author":[{"given":"Houcai","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjie","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa, Carver College of Medicine, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa, Carver College of Medicine, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Griffin","year":"2003","journal-title":"Semin Hematol"},{"key":"3","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1007\/s002800100310","article-title":"ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy","volume":"48","author":"Druker","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Sawyers","year":"2001","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses","volume":"101","author":"Talpaz","year":"2003","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.leukres.2003.08.002","article-title":"Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase","volume":"28","author":"Jarosova","year":"2004","journal-title":"Leuk Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Perrotti","year":"2004","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Skorski","year":"2010","journal-title":"J Clin Invest"},{"key":"9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4. 5-year follow-up","volume":"103","author":"Hochhaus","year":"2005","journal-title":"Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Stone","year":"2002","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Hughes","year":"2003","journal-title":"Blood"},{"key":"13","first-page":"337","article-title":"Establishment of an imatinib resistant cell line K562\/G01 and its characterization. [Article in Chinese]","volume":"25","author":"Yang","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.18632\/oncotarget.360","article-title":"Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells","volume":"2","author":"Auberger","year":"2011","journal-title":"Oncotarget"},{"key":"15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.leu.2404463","article-title":"Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia","volume":"21","author":"Mahon","year":"2007","journal-title":"Leukemia"},{"key":"16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","author":"Senina","year":"2015","journal-title":"Leukemia"},{"key":"17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.leukres.2013.11.012","article-title":"p-Stat3 and bcr\/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy","volume":"38","author":"Khalaf","year":"2014","journal-title":"Leuk Res"},{"key":"18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fonc.2012.00030","article-title":"Role of STAT3 in Transformation and Drug Resistance in CML","volume":"2","author":"Hazlehurst","year":"2012","journal-title":"Front Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression","volume":"117","author":"Clark","year":"2011","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12253-013-9709-y","article-title":"Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes","volume":"20","author":"Kitagawa","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190601186002","article-title":"Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation","volume":"48","author":"Brdicka","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Mountford","year":"2006","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.3892\/or.2014.3098","article-title":"Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia","volume":"31","author":"Luo","year":"2014","journal-title":"Oncol Rep"},{"key":"24","doi-asserted-by":"crossref","first-page":"e111611","DOI":"10.1371\/journal.pone.0111611","article-title":"A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1074\/jbc.M109.075788","article-title":"Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation","volume":"285","author":"Ohnishi","year":"2010","journal-title":"J Biol Chem"},{"key":"26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3892\/ol.2013.1159","article-title":"Notch2 inhibits proliferation of chronic myeloid leukemia cells","volume":"5","author":"Chen","year":"2013","journal-title":"Oncol Lett"},{"key":"27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/338438a0","article-title":"Identification of the long ubiquitin extension as ribosomal protein S27a","volume":"338","author":"Rechsteiner","year":"1989","journal-title":"Nature"},{"key":"28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/cc.9.3.11152","article-title":"Degradation of ubiquitin: the fate of the cellular reaper","volume":"9","author":"Ciechanover","year":"2010","journal-title":"Cell Cycle"},{"key":"29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molcel.2009.03.006","article-title":"How common are extraribosomal functions of ribosomal proteins?","volume":"34","author":"McIntosh","year":"2009","journal-title":"Mol Cell"},{"key":"30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0968-0004(96)20011-8","article-title":"Extraribosomal functions of ribosomal proteins","volume":"21","author":"Wool","year":"1996","journal-title":"Trends Biochem Sci"},{"key":"31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bbrc.2014.03.086","article-title":"RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells","volume":"446","author":"Wang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2006.06161.x","article-title":"BCR-ABL activates STAT3 via JAK and MEK pathways in human cells","volume":"134","author":"Turhan","year":"2006","journal-title":"Br J Haematol"},{"key":"33","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1158\/1535-7163.MCT-12-0550","article-title":"Suppression of survivin induced by a BCR-ABL\/JAK2\/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs","volume":"12","author":"Vigneri","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bjc.1992.12","article-title":"Differential expression of translation-associated genes in benign and malignant human breast tumours","volume":"65","author":"Varley","year":"1992","journal-title":"Br J Cancer"},{"key":"35","first-page":"6677","article-title":"Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells","volume":"51","author":"Ichihara","year":"1991","journal-title":"Cancer Res"},{"key":"36","first-page":"1916","article-title":"Ubiquitin-ribosomal protein S27a gene overexpressed in human colorectal carcinoma is an early growth response gene","volume":"53","author":"Chen","year":"1993","journal-title":"Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00280-009-1109-3","article-title":"LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate","volume":"65","author":"Abdelhay","year":"2010","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T18:56:07Z","timestamp":1591383367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":37,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,4,5]]}},"alternative-id":["7888","26942564"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7888","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}